Which patients benefit from potassium binders?10' education - Feb. 15, 2022 - Kevin Damman, MD, PhD – Groningen, The Netherlands
Video navigation menu
- RAASi as cornerstone of treatment for CKD and HF 0:29
- Hyperkalemia: the scope of the problem 2:26
- Which patients are at risk of hyperkalemia 4:56
- Summary 5:45
Which factors reduce potassium excretion and increase risk of hyperkalemia?
- A. diabetes, use of RAASi, use of beta-blockers
- B. CKD, diabetes, use of loop diuretics
- C. CKD, diabetes, use of RAASi
- D. higher age, CKD, use of loop diuretics
This lecture by Kevin Damman is part of a series titled "3 Things a cardiologist needs to know about potassium binders".
This program has been designed to provide cardiologists insights in the role of potassium binding as RAASi enabling therapy in the management of patients with cardiorenal disease and /or heart failure. This series consists of three presentations.
Kevin Damman is clinical cardiologist and head of the heart transplant and left ventricular assist device program at the University Medical Center Groningen, The Netherlands.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from Vifor.